top of page

Data support Opdivo as new standard of care in mRCC, says GlobalData

Four abstracts presented at this year’s American Society of Clinical Oncology (ASCO) conference strengthen the body of research into Bristol-Myers Squibb’s Opdivo (nivolumab), hailing it as the new standard of care in recurrent metastatic renal cell carcinoma (mRCC), according to analysts with research and consulting firm GlobalData.

Click on this link for more information



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page